Clinical Trials Sponsored by Asahi Kasei Pharma America Corporation

Total 26 results

Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
Asahi Kasei Pharma America Corporation

Withdrawn

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

Sepsis and Coagulopathy
Asahi Kasei Pharma Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

Lupus Nephritis

China
Asahi Kasei Pharma Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

Nephrotic Syndrome

China
Asahi Kasei Pharma Corporation

Completed

Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment

Disseminated Intravascular Coagulation

Japan
Asahi Kasei Pharma Corporation

Completed

Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke

Severe Upper Limb Hemiplegia

Japan
Asahi Kasei Pharma Corporation

Completed

Study of AK156 in Primary Osteoporosis Patients

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Asahi Kasei Pharma Corporation

Completed

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Postoperative Stage II/III Colon Cancer

Japan
Asahi Kasei Pharma Corporation

Completed

Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

Diabetes

United States
Asahi Kasei Pharma Corporation

Completed

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Japan
Asahi Kasei Pharma Corporation

Completed

Clinical Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Completed

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Deep Mycosis

Japan
Asahi Kasei Pharma Corporation

Completed

Collagenase Option for Reduction of Dupuytren's Contracture in Japan (CORD-J)

Dupuytren's Contracture

Japan
Asahi Kasei Pharma Corporation

Completed

A Phase I Study of AK159 in Healthy Postmenopausal Women

Osteoporosis

Japan
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Poland, Ukraine, Germany, Hungary, United Kingdom, Slovakia, Czech Republic
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Germany, Romania, Hungary, Lithuania, Czech Republic, United Kingdom
Asahi Kasei Pharma Corporation
Emergent Clinical Consulting, LLC

Terminated

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (ENHANCE)

Spinal Stenosis | Degenerative Spondylolisthesis

Canada
Cortria Corporation
PPD; Pharmena North America

Completed

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Healthy

Canada
Nuance Pharma (shanghai) Co., Ltd
Laboratory Corporation of America

Recruiting

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Tokai University
Abbott Medical Devices; Kaneka Medical America LLC; Terumo Medical Corporation; Asahi Intech and other collaborators

Completed

Guidewire for Chronic Total Occlusion (G-FORCE)

Coronary Occlusion

Japan
Vifor (International) Inc.
Labcorp Corporation of America Holdings, Inc

Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia (VITHAL)

Beta-Thalassemia | Non-transfusion-dependent Thalassemia

Greece, Israel, Italy, Lebanon, Thailand
Laminar Pharmaceuticals
Laboratory Corporation of America; Northern Institute for Cancer Research,... and other collaborators

Recruiting

LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO)

Glioblastoma Multiforme | Primary Glioblastoma

Spain, Italy, United Kingdom, France, Israel
Amsterdam UMC, location VUmc
Roche Pharma AG; Baxter Healthcare Corporation; UMC Utrecht; Fresenius Medical... and other collaborators

Completed

Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients (CONTRAST)

Cardiovascular Disease | End-stage Renal Disease

Netherlands, Norway, Canada
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaborators

Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19 (Sisonke)

SARS (Severe Acute Respiratory Syndrome)

South Africa
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; Right to Care and other collaborators

Recruiting

Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. (Sisonke Boost)

SARS CoV 2 Infection

South Africa

Clinical Trials Sponsored by Asahi Kasei Pharma America Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations